Patients HCPs

For US audiences only.

Prescribing Information, including Boxed WARNING
Novartis Patient Support™ 1-855-441-4363

Tell us about your One Dose Life. Lab tests and administration of oral corticosteroids are required before and after injection. Scarlette lives with SMA and hasn’t received ITVISMA. She was compensated for her time.

Sharing your unique experience can inspire countless others living with spinal muscular atrophy (SMA). Let the story of your One Dose Life be heard by joining our team of ambassadors.

We'd love to hear your story

Call 1-212-885-3010 or email us at [email protected].

Share your story

IMPORTANT SAFETY INFORMATION

What is the most important safety information I should know about ITVISMA?

ITVISMA can increase liver enzyme levels and cause hepatotoxicity.
Patients will receive an oral corticosteroid medication before and after ITVISMA injection and will undergo regular blood tests to monitor liver function.
Patients and caregivers should contact the patient’s doctor immediately if the patient’s skin and/or whites of the eyes become yellowish, if the patient misses a dose of corticosteroid or vomits it up, or if the patient experiences a decrease in alertness.

INDICATION

What is ITVISMA?

ITVISMA is a prescription gene therapy used to treat adults and children 2 years of age and older with spinal muscular atrophy (SMA). ITVISMA is given as a one-time intrathecal injection.

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION

Contact Us
Non-US Residents
Sitemap
Your Privacy Choices

Use of website is governed by the Terms of Use and Privacy Policy.

Consumer Health Privacy Policy

Follow ITVISMA on social media

11/25 FA-11499568